Literature DB >> 23949643

Prostate positioning using cone-beam computer tomography based on manual soft-tissue registration: interobserver agreement between radiation oncologists and therapists.

B A Jereczek-Fossa1, C Pobbiati, L Santoro, C Fodor, P Fanti, S Vigorito, G Baroni, D Zerini, O De Cobelli, R Orecchia.   

Abstract

PURPOSE: To check the interobserver agreement between radiation oncologists and therapists (RTT) using an on- and off-line cone-beam computer tomography (CBCT) protocol for setup verification in the radiotherapy of prostate cancer.
MATERIALS AND METHODS: The CBCT data from six prostate cancer patients treated with hypofractionated intensity-modulated radiotherapy (IMRT) were independently reviewed off-line by four observers (one radiation oncologist, one junior and two senior RTTs) and benchmarked with on-line CBCT positioning performed by a radiation oncologist immediately prior to treatment. CBCT positioning was based on manual soft-tissue registration. Agreement between observers was evaluated using weighted Cohen's kappa statistics.
RESULTS: In total, 152 CBCT-based prostate positioning procedures were reviewed by each observer. The mean (± standard deviation) of the differences between off- and on-line CBCT-simCT registration translations along the three directions (antero-posterior, latero-lateral and cranio-caudal) and rotation around the antero-posterior axis were -0.7 (3.6) mm, 1.9 (2.7) mm, 0.9 (3.6) mm and -1.8 (5.0) degrees, respectively. Satisfactory interobserver agreement was found, being substantial (weighted kappa >0.6) in 10 of 16 comparisons and moderate (0.41-0.60) in the remaining six comparisons.
CONCLUSIONS: CBCT interpretation performed by RTTs is comparable to that of radiation oncologists. Our study might be helpful in the quality assurance of radiotherapy and the optimization of competencies. Further investigation should include larger sample sizes, a greater number of observers and validated methodology in order to assess interobserver variability and its impact on high-precision prostate cancer IGRT. In the future, it should enable the wider implementation of complex and evolving radiotherapy technologies.

Entities:  

Mesh:

Year:  2013        PMID: 23949643     DOI: 10.1007/s00066-013-0387-1

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  32 in total

1.  Observer variability when evaluating patient movement from electronic portal images of pelvic radiotherapy fields.

Authors:  D Geraint Lewis; Karen R Ryan; Cyril W Smith
Journal:  Radiother Oncol       Date:  2004-12-23       Impact factor: 6.280

2.  Understanding interobserver agreement: the kappa statistic.

Authors:  Anthony J Viera; Joanne M Garrett
Journal:  Fam Med       Date:  2005-05       Impact factor: 1.756

Review 3.  The role of the GI radiographer: a United Kingdom perspective.

Authors:  Julie Nightingale; Peter Hogg
Journal:  Radiol Technol       Date:  2007 Mar-Apr

4.  Radiographers' role in radiological reporting: a model to support future demand.

Authors:  Tony N Smith; Marilyn Baird
Journal:  Med J Aust       Date:  2007-06-18       Impact factor: 7.738

Review 5.  Radiation medicine practice in the image-guided radiation therapy era: new roles and new opportunities.

Authors:  Elizabeth White; Gabrielle Kane
Journal:  Semin Radiat Oncol       Date:  2007-10       Impact factor: 5.934

6.  Toxicity and outcome of pelvic IMRT for node-positive prostate cancer.

Authors:  A-C Müller; J Lütjens; M Alber; F Eckert; M Bamberg; D Schilling; C Belka; U Ganswindt
Journal:  Strahlenther Onkol       Date:  2012-10-11       Impact factor: 3.621

7.  Moderate hypofractionation and simultaneous integrated boost with volumetric modulated arc therapy (RapidArc) for prostate cancer. Report of feasibility and acute toxicity.

Authors:  F Alongi; A Fogliata; P Navarria; A Tozzi; P Mancosu; F Lobefalo; G Reggiori; A Clivio; L Cozzi; M Scorsetti
Journal:  Strahlenther Onkol       Date:  2012-09-29       Impact factor: 3.621

8.  Migration of intraprostatic fiducial markers and its influence on the matching quality in external beam radiation therapy for prostate cancer.

Authors:  Guila Delouya; Jean-François Carrier; Dominic Béliveau-Nadeau; David Donath; Daniel Taussky
Journal:  Radiother Oncol       Date:  2010-04-08       Impact factor: 6.280

9.  Feasibility of CBCT-based target and normal structure delineation in prostate cancer radiotherapy: multi-observer and image multi-modality study.

Authors:  Carola Lütgendorf-Caucig; Irina Fotina; Markus Stock; Richard Pötter; Gregor Goldner; Dietmar Georg
Journal:  Radiother Oncol       Date:  2010-12-20       Impact factor: 6.280

10.  Quality of life after intensity-modulated radiotherapy for prostate cancer with a hydrogel spacer. Matched-pair analysis.

Authors:  M Pinkawa; M D Piroth; R Holy; N Escobar-Corral; M Caffaro; V Djukic; J Klotz; M J Eble
Journal:  Strahlenther Onkol       Date:  2012-08-31       Impact factor: 3.621

View more
  9 in total

1.  Hydrogel injection reduces rectal toxicity after radiotherapy for localized prostate cancer.

Authors:  Michael Pinkawa; Vanessa Berneking; Liane König; Dilini Frank; Marilou Bretgeld; Michael J Eble
Journal:  Strahlenther Onkol       Date:  2016-09-08       Impact factor: 3.621

2.  Effect of dose reduction on image registration and image quality for cone-beam CT in radiotherapy.

Authors:  B Loutfi-Krauss; J Köhn; N Blümer; K Freundl; T Koch; E Kara; C Scherf; C Rödel; U Ramm; J Licher
Journal:  Strahlenther Onkol       Date:  2014-09-20       Impact factor: 3.621

3.  Semi-automated prediction approach of target shifts using machine learning with anatomical features between planning and pretreatment CT images in prostate radiotherapy.

Authors:  Yudai Kai; Hidetaka Arimura; Kenta Ninomiya; Tetsuo Saito; Yoshinobu Shimohigashi; Akiko Kuraoka; Masato Maruyama; Ryo Toya; Natsuo Oya
Journal:  J Radiat Res       Date:  2020-03-23       Impact factor: 2.724

4.  In vivo measurement of dose distribution in patients' lymphocytes: helical tomotherapy versus step-and-shoot IMRT in prostate cancer.

Authors:  Felix Zwicker; Benedict Swartman; Falk Roeder; Florian Sterzing; Henrik Hauswald; Christian Thieke; Klaus-Josef Weber; Peter E Huber; Kai Schubert; Jürgen Debus; Klaus Herfarth
Journal:  J Radiat Res       Date:  2014-10-31       Impact factor: 2.724

5.  Evaluation of the XVI dual registration tool for image-guided radiotherapy in prostate cancer.

Authors:  Filipa Sousa; Younes Jourani; Robbe Van den Begin; François-Xavier Otte; Sara Ridai; Maxime Desle; Angela Ferreira; Radia Ahmimed; Moniek C M van Klink-de Goeij; Dirk Van Gestel
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2021-04-20

6.  Evaluating the impact of possible interobserver variability in CBCT-based soft-tissue matching using TCP/NTCP models for prostate cancer radiotherapy.

Authors:  Xiangbin Zhang; Xin Wang; Xiaoyu Li; Li Zhou; Shihong Nie; Changhu Li; Xuetao Wang; Guyu Dai; Zhonghua Deng; Renming Zhong
Journal:  Radiat Oncol       Date:  2022-04-01       Impact factor: 3.481

7.  The emerging role of radiation therapists in the contouring of organs at risk in radiotherapy: analysis of inter-observer variability with radiation oncologists for the chest and upper abdomen.

Authors:  Simona Arculeo; Eleonora Miglietta; Fabrizio Nava; Anna Morra; Maria Cristina Leonardi; Stefania Comi; Delia Ciardo; Massimo Sarra Fiore; Marianna Alessandra Gerardi; Matteo Pepa; Simone Giovanni Gugliandolo; Lorenzo Livi; Roberto Orecchia; Barbara Alicja Jereczek-Fossa; Samantha Dicuonzo
Journal:  Ecancermedicalscience       Date:  2020-01-06

8.  Observer uncertainties of soft tissue-based patient positioning in IGRT.

Authors:  Taka-Aki Hirose; Hidetaka Arimura; Jun-Ichi Fukunaga; Saiji Ohga; Tadamasa Yoshitake; Yoshiyuki Shioyama
Journal:  J Appl Clin Med Phys       Date:  2020-01-20       Impact factor: 2.102

9.  RTT-led IGRT for cervix cancer; training, implementation and validation.

Authors:  S E Alexander; N Hopkins; S Lalondrelle; A Taylor; K Titmarsh; H A McNair
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2019-12-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.